Bioactivation of the Anticancer Agent CPT-11 to SN-38 by Human Hepatic Microsomal Carboxylesterases and the in Vitro Assessment of Potential Drug Interactions
Overview
Authors
Affiliations
Human hepatic microsomes were used to investigate the carboxylesterase-mediated bioactivation of CPT-11 to the active metabolite, SN-38. SN-38 formation velocity was determined by HPLC over a concentration range of 0.25-200 microM CPT-11. Biphasic Eadie Hofstee plots were observed in seven donors, suggesting that two isoforms catalyzed the reaction. Analysis by nonlinear least squares regression gave KM estimates of 129-164 microM with a Vmax of 5.3-17 pmol/mg/min for the low affinity isoform. The high affinity isoform had KM estimates of 1.4-3.9 microM with Vmax of 1.2-2.6 pmol/mg/min. The low KM carboxylesterase may be the main contributor to SN-38 formation at clinically relevant hepatic concentrations of CPT-11. Using standard incubation conditions, the effects of potential inhibitors of carboxylesterase-mediated CPT-11 hydrolysis were evaluated at concentrations >/= 21 microM. Positive controls bis-nitrophenylphosphate (BNPP) and physostigmine decreased CPT-11 hydrolysis to 1.3-3.3% and 23% of control values, respectively. Caffeine, acetylsalicylic acid, coumarin, cisplatin, ethanol, dexamethasone, 5-fluorouracil, loperamide, and prochlorperazine had no statistically significant effect on CPT-11 hydrolysis. Small decreases were observed with metoclopramide (91% of control), acetaminophen (93% of control), probenecid (87% of control), and fluoride (91% of control). Of the compounds tested above, based on these in vitro data, only the potent inhibitors of carboxylesterase (BNPP, physostigmine) have the potential to inhibit CPT-11 bioactivation if administered concurrently. The carboxylesterase-mediated hydrolysis of alpha-naphthyl acetate (alpha-NA) was used to determine whether CPT-11 was an inhibitor of hydrolysis of high turnover substrates of carboxylesterases. Inhibition of alpha-NA hydrolysis by CPT-11 was determined relative to positive controls BNPP and NaF. Incubation with microsomes pretreated with CPT-11 (80-440 microM) decreased alpha-naphthol formation to approximately 80% of control at alpha-NA concentrations of 50-800 microM. The inhibitors BNPP (360 microM) and NaF (500 microM) inhibited alpha-naphthol formation to 9-10% of control and to 14-20% of control, respectively. Therefore, CPT-11-sensitive carboxylesterase isoforms may account for only 20% of total alpha-NA hydrolases. Thus, CPT-11 is unlikely to significantly inhibit high turnover, nonselective substrates of carboxylesterases.
Role of Cytochrome P450 3A4 in Cancer Drug Resistance: Challenges and Opportunities.
Pandey S, Verma S, Upreti S, Mishra A, Yadav N, Dwivedi-Agnihotri H Curr Drug Metab. 2024; 25(4):235-247.
PMID: 38984579 DOI: 10.2174/0113892002312369240703102215.
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M, van Doorn L, Kloet E, Van Veggel A, Matic M, de Neijs M Clin Pharmacokinet. 2023; 62(11):1589-1597.
PMID: 37715926 PMC: 10582127. DOI: 10.1007/s40262-023-01279-7.
How Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?.
Mendes I, Vale N Int J Mol Sci. 2023; 24(14).
PMID: 37511612 PMC: 10380870. DOI: 10.3390/ijms241411855.
Antitumor activity of irinotecan with ellagic acid in C6 glioma cells.
Cetin A, Biltekin B, Ozevren H Rev Assoc Med Bras (1992). 2022; 68(7):939-944.
PMID: 35946772 PMC: 9574968. DOI: 10.1590/1806-9282.20220130.
Atasilp C, Biswas M, Jinda P, Nuntharadthanaphong N, Rachanakul J, Hongkaew Y Clin Transl Sci. 2022; 15(7):1613-1633.
PMID: 35506159 PMC: 9283744. DOI: 10.1111/cts.13277.